Regeneron's RNA interference therapy cemdisiran, licensed from Alnylam, achieved success in pivotal phase III trials in generalized myasthenia gravis (MG). The siRNA agent, as monotherapy, showed a 74% reduction in complement factor 5 and meaningful improvements in daily living activities. Plans are underway for FDA filing in early 2026, potentially providing a new therapeutic option in this autoimmune neuromuscular disease landscape.